Johnson & Johnson

© Getty Images

J&J’s Akeega FDA approval to heat up PARP battle

By Isabel Cameron

The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).


Janssen discontinues Phase 3 HIV vaccine trial

By Rachel Arthur

Janssen’s experimental HIV vaccine regimen was found to be safe but ineffective in the Phase 3 Mosaico clinical trial: and as a result the company is discontinuing the study.


Johnson & Johnson to spin off consumer health business

By Rachel Arthur

Johnson & Johnson has announced its intent to separate its Consumer Health business into a new publicly traded company: allowing J&J to put a sharpened focus on pharmaceuticals and medical devices.


Merck to help manufacture J&J COVID-19 vaccine

By Rachel Arthur

Merck’s US facilities will help manufacture Johnson & Johnson’s COVID-19 vaccine: which a $268.8m injection from the US government helping it adapt existing facilities for COVID-19 vaccines and medicines.


FDA says J&J COVID-19 vaccine is effective and safe

By Rachel Arthur

The FDA has outlined its analysis of Johnson & Johnson's single-shot COVID-19 vaccine, ahead of a meeting of the Vaccines and Related Biological Products Advisory Committee Meeting to assess the candidate's application for Emergency Use...


J&J submits EUA application for single-shot COVID-19 vaccine

By Rachel Arthur

J&J pledges to start shipping doses of its COVID-19 vaccine in the US as soon as Emergency Use Authorization (EUA) is received from the Food and Drug Administration, while it plans to apply for Conditional Marketing Authorization in the EU in the...


Janssen acquires rights to novel AMD gene therapy

By Rachel Arthur

Janssen Pharmaceuticals, Inc. has acquired the rights to Hemera Biosciences’ investigational gene therapy HMR59: which has been designed to help preserve vision in patients with severe age-related macular degeneration (AMD).

J&J has now taken its COVID-19 vaccine into Phase 3 trials for both a 1-dose and 2-dose regimen. Pic:getty/JHDTstockimages

J&J launches Phase 3 trial for 2-dose COVID-19 vaccine

By Rachel Arthur

Johnson & Johnson has launched a second global Phase 3 trial for its Janssen COVID-19 vaccine candidate: this time exploring a 2-dose regimen (its existing Phase 3 trial is for a 1-dose regimen).


Johnson & Johnson starts Phase 3 trial for COVID-19 vaccine

By Rachel Arthur

Johnson & Johnson has launched its pivotal global Phase 3 trial for its COVID-19 vaccine candidate: anticipating the first batches of its vaccine will be available for emergency use authorization in early 2021.